The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells

Haematologica. 2009 Mar;94(3):430-1. doi: 10.3324/haematol.13865. Epub 2009 Jan 30.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antigens, CD34 / blood
  • Antineoplastic Agents / therapeutic use
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 5 / genetics*
  • Cytogenetic Analysis
  • Female
  • Hematopoietic Stem Cells / cytology
  • Hematopoietic Stem Cells / immunology
  • Hematopoietic Stem Cells / metabolism*
  • Humans
  • In Situ Hybridization, Fluorescence
  • Karyotyping
  • Lenalidomide
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics
  • Myelodysplastic Syndromes / pathology
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use
  • Treatment Outcome

Substances

  • Antigens, CD34
  • Antineoplastic Agents
  • Thalidomide
  • Lenalidomide